NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,492.76 mln
Float94.63 mln
Earnings Date07/30/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.65
Likely reliable
1-Year Forecast
51.53
Transformational upside
Relative Strength
69
/ 100
Outperforming
Debt / Equity
-0.45
Negative equity
ROE
-599
Deeply negative
Business Description
Ultragenyx Pharmaceutical is a US-based drug development company dedicated to creating treatments for rare and ultra-rare genetic conditions, serving patients across North America, Europe, Latin America, the Middle East, Africa, and the Asia-Pacific region. The company has brought several approved medicines to market, including treatments for conditions that affect bone health, enzyme function, and fat metabolism, while also advancing a robust pipeline of gene therapies and other novel approaches through late-stage clinical trials. Ultragenyx works alongside a broad network of research institutions and biotechnology partners to accelerate the development of new options for patient populations that have historically had very few treatment choices. Founded in 2010 and based in Novato, California, the company remains focused on addressing some of the most underserved areas of medicine.